-
1
-
-
0026688428
-
Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor-β1 and cancer chemotherapy compounds in myeloid leukemic cells
-
Lotem J, Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor-β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992, 80:1750-1757.
-
(1992)
Blood
, vol.80
, pp. 1750-1757
-
-
Lotem, J.1
Sachs, L.2
-
2
-
-
0026533427
-
GM-CSF and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effects on clonogenic cells from patients with acute myeloid leukemia
-
Hiddemann W, Kiehl M, Zuhlsdorf M, Busemann C, Schleyer E, Wormann B, Buchner T: GM-CSF and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effects on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 1992, 19:31-37.
-
(1992)
Semin Oncol
, vol.19
, pp. 31-37
-
-
Hiddemann, W.1
Kiehl, M.2
Zuhlsdorf, M.3
Busemann, C.4
Schleyer, E.5
Wormann, B.6
Buchner, T.7
-
3
-
-
0027978963
-
Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia
-
Gandhi V, Du M, Kantarjian HM, Plunkett W: Effect of granulocyte-macrophage colony-stimulating factor on the metabolism of arabinosylcytosine triphosphate in blasts during therapy of patients with chronic myelogenous leukemia. Leukemia 1994, 8:1463-1468.
-
(1994)
Leukemia
, vol.8
, pp. 1463-1468
-
-
Gandhi, V.1
Du, M.2
Kantarjian, H.M.3
Plunkett, W.4
-
4
-
-
0025950205
-
Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity
-
Koistinen P, Wang C, Curtis JE, McCulloch EA: Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from Ara-C toxicity. Leukemia 1991, 5:789-795.
-
(1991)
Leukemia
, vol.5
, pp. 789-795
-
-
Koistinen, P.1
Wang, C.2
Curtis, J.E.3
McCulloch, E.A.4
-
5
-
-
0028580535
-
Filgrastim in patients with chemotherapy-induced febrile neutropenia: A double blind, placebo-controlled trial
-
Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, Sheridan WP, Kefford RF, Cebon J, Olver I, et al.: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double blind, placebo-controlled trial. Ann Intern Med 1994, 121:492-501.
-
(1994)
Ann Intern Med
, vol.121
, pp. 492-501
-
-
Maher, D.W.1
Lieschke, G.J.2
Green, M.3
Bishop, J.4
Stuart-Harris, R.5
Wolf, M.6
Sheridan, W.P.7
Kefford, R.F.8
Cebon, J.9
Olver, I.10
-
6
-
-
0025800331
-
Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF)
-
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, et al.: Reduction in the incidence of chemotherapy-induced febrile neutropenia in patients with small cell lung cancer by granulocyte colony-stimulating factor (R-metG-CSF). N Engl J Med 1991, 325:164-171.
-
(1991)
N Engl J Med
, vol.325
, pp. 164-171
-
-
Crawford, J.1
Ozer, H.2
Stoller, R.3
Johnson, D.4
Lyman, G.5
Tabbara, I.6
-
7
-
-
0028891412
-
Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy
-
De Haan G, Engel C, Dontje B, Loeffler M, Nijhof W: Hemotoxicity by prolonged etoposide administration to mice can be prevented by simultaneous growth factor therapy. Cancer Res 1995, 55:324-329. Simultaneous administration of etoposide and G-CSF protected normal mice from the subsequent development of neutropenia.
-
(1995)
Cancer Res
, vol.55
, pp. 324-329
-
-
De Haan, G.1
Engel, C.2
Dontje, B.3
Loeffler, M.4
Nijhof, W.5
-
8
-
-
0023945042
-
Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
-
Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, Yagoda A, Fain K, Moore MA, Clarkson B, et al.: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988, 318:1414-1422.
-
(1988)
N Engl J Med
, vol.318
, pp. 1414-1422
-
-
Gabrilove, J.L.1
Jakubowski, A.2
Scher, H.3
Sternberg, C.4
Wong, G.5
Grous, J.6
Yagoda, A.7
Fain, K.8
Moore, M.A.9
Clarkson, B.10
-
9
-
-
0023682969
-
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression
-
Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, Oette D, Whitley M, Frei E, Schnipper LE: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 1988, 319:593-598.
-
(1988)
N Engl J Med
, vol.319
, pp. 593-598
-
-
Antman, K.S.1
Griffin, J.D.2
Elias, A.3
Socinski, M.A.4
Ryan, L.5
Cannistra, S.A.6
Oette, D.7
Whitley, M.8
Frei, E.9
Schnipper, L.E.10
-
10
-
-
0026732612
-
Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy
-
Meropol NJ, Miller LL, Korn EL, Braitman LE, MacDermott ML, Schuchter LM: Severe myelosuppression resulting from concurrent administration of granulocyte colony-stimulating factor and cytotoxic chemotherapy. J Natl Cancer Inst 1992, 84:1201-1203.
-
(1992)
J Natl Cancer Inst
, vol.84
, pp. 1201-1203
-
-
Meropol, N.J.1
Miller, L.L.2
Korn, E.L.3
Braitman, L.E.4
MacDermott, M.L.5
Schuchter, L.M.6
-
11
-
-
0029883729
-
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
-
Rowinsky EK, Grochow LB, Sartorius SE, Bowling MK, Kaufmann SH, Peereboom D, Donehower RC: Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors. J Clin Oncol 1996, 14:1224-1235. Higher maximally tolerated doses of topotecan were achieved when initiation of G-CSF therapy was delayed for 24 hours following chemotherapy compared with concurrent administration.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1224-1235
-
-
Rowinsky, E.K.1
Grochow, L.B.2
Sartorius, S.E.3
Bowling, M.K.4
Kaufmann, S.H.5
Peereboom, D.6
Donehower, R.C.7
-
12
-
-
0028217482
-
Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma
-
Grem JL, McAtee N, Murphy RF, Hamilton JM, Balls F, Steinberg S, Arbuck SG, Setser A, Jordan E, Chen A, et al.: Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. J Clin Oncol 1994, 12:560-568.
-
(1994)
J Clin Oncol
, vol.12
, pp. 560-568
-
-
Grem, J.L.1
McAtee, N.2
Murphy, R.F.3
Hamilton, J.M.4
Balls, F.5
Steinberg, S.6
Arbuck, S.G.7
Setser, A.8
Jordan, E.9
Chen, A.10
-
13
-
-
0027332976
-
A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies
-
Shaffer DW, Smith LS, Burris HA, Clark GM, Eckardt JR, Fields SM, Weiss GR, Rinaldi DA, Bowen KJ, Kuhn JG, et al.: A randomized phase I trial of chronic oral etoposide with or without granulocyte-macrophage colony-stimulating factor in patients with advanced malignancies. Cancer Res 1993, 53:5929-5933.
-
(1993)
Cancer Res
, vol.53
, pp. 5929-5933
-
-
Shaffer, D.W.1
Smith, L.S.2
Burris, H.A.3
Clark, G.M.4
Eckardt, J.R.5
Fields, S.M.6
Weiss, G.R.7
Rinaldi, D.A.8
Bowen, K.J.9
Kuhn, J.G.10
-
14
-
-
0028844775
-
A pilot study of the biologic and therapeutic effects of granulocyte colony-stimulating factor (filgrastim) in patients with acute myelogenous leukemia
-
0 into the S phase.
-
(1995)
Leukemia
, vol.9
, pp. 1799-1804
-
-
Jakubowski, A.1
Gordon, M.2
Tafuri, A.3
Schuster, S.4
Andreeff, M.5
Shieh, J.-H.6
Vincent, M.7
Gabrilove, J.8
-
15
-
-
0028256428
-
A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia
-
Ohno R, Naoe T, Kanamaru A, Yoshida M, Hiraoka A, Kobayashi T, Ueda T, Minami S, Morishima Y, Saito Y, et al.: A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994, 83:2086-2092.
-
(1994)
Blood
, vol.83
, pp. 2086-2092
-
-
Ohno, R.1
Naoe, T.2
Kanamaru, A.3
Yoshida, M.4
Hiraoka, A.5
Kobayashi, T.6
Ueda, T.7
Minami, S.8
Morishima, Y.9
Saito, Y.10
-
16
-
-
8944234342
-
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
-
Zittoun R, Suciu S, Mandelli F, de Witte T, Thaler J, Stryckmans P, Hayat M, Peetermans M, Cadiou M, Solbu G, et al.: Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996, 14:2150-2159. Administration of GM-CSF during induction therapy provides no therapeutic benefit in the treatment of acute myelogenous leukemia. Use of this cytokine after chemotherapy was associated with a reduction in the complete remission rate and adverse effects such as fluid retention.
-
(1996)
J Clin Oncol
, vol.14
, pp. 2150-2159
-
-
Zittoun, R.1
Suciu, S.2
Mandelli, F.3
De Witte, T.4
Thaler, J.5
Stryckmans, P.6
Hayat, M.7
Peetermans, M.8
Cadiou, M.9
Solbu, G.10
-
17
-
-
0029978349
-
Use of cytokines in the treatment of acute myelocytic leukemia: A critical review
-
Geller RB: Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996, 14:1371-1382. A review of six phase III trials that used a CSF during AML induction found this combination to be safe with an improvement in neutrophil recovery.
-
(1996)
J Clin Oncol
, vol.14
, pp. 1371-1382
-
-
Geller, R.B.1
-
18
-
-
0029067674
-
Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized phase III trial
-
Ottman OG, Hoelzer D, Gracien E, Ganser A, Kelly K, Reutzel R, Lipp T, Busch FW, Schwonzen M, Heil G, et al.: Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995, 86:444-450. Administration of G-CSF during ALL induction therapy was found to be safe and led to a shorter duration of neutropenia and earlier completion of chemotherapy.
-
(1995)
Blood
, vol.86
, pp. 444-450
-
-
Ottman, O.G.1
Hoelzer, D.2
Gracien, E.3
Ganser, A.4
Kelly, K.5
Reutzel, R.6
Lipp, T.7
Busch, F.W.8
Schwonzen, M.9
Heil, G.10
-
19
-
-
0029872332
-
Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation
-
Kanda Y, Akiyama H, Tanikawa S, Sakamaki H, Sasaki T, Takamoto S, Yasusuke O: Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation. Am J Hematol 1996, 51:265-268. Two pateints who were treated with high-dose cyclophosphamide, etoposide, and busulfan were concurrently given G-CSF and both experienced hepatic veno-occlusive disease.
-
(1996)
Am J Hematol
, vol.51
, pp. 265-268
-
-
Kanda, Y.1
Akiyama, H.2
Tanikawa, S.3
Sakamaki, H.4
Sasaki, T.5
Takamoto, S.6
Yasusuke, O.7
-
20
-
-
9044220233
-
Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine
-
Weintraub M, Adde MA, Venzon DJ, Shad AT, Horak ID, Neely JE, Seibel NL, Gootenberg J, Arndt C, Nieder ML, Magrath IT: Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol 1996, 14:935-940. Despite the fact that overlap of CSF administration with vincristine occurred in only one of the three doses in each cycle, severe atypical neuropathy was evident in 39% of patients compared with approximately 4% of control subjects.
-
(1996)
J Clin Oncol
, vol.14
, pp. 935-940
-
-
Weintraub, M.1
Adde, M.A.2
Venzon, D.J.3
Shad, A.T.4
Horak, I.D.5
Neely, J.E.6
Seibel, N.L.7
Gootenberg, J.8
Arndt, C.9
Nieder, M.L.10
Magrath, I.T.11
-
21
-
-
0029975952
-
Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor for intermediate-grade non-Hodgkin's lymphoma
-
Niitsu N, Umeda M: Biweekly COP-BLAM (cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin and procarbazine) regimen combined with granulocyte colony-stimulating factor for intermediate-grade non-Hodgkin's lymphoma. Eur J Haematol 1996, 56:163-167. A minimal overlap of G-CSF with the COP-BLAM regimen allowed for a shortened interval between chemotherapy cycles without accentuating toxicity.
-
(1996)
Eur J Haematol
, vol.56
, pp. 163-167
-
-
Niitsu, N.1
Umeda, M.2
|